Vaxcyte Advances to Second Stage of Ongoing Phase 2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Infants
Advancement to Stage 2 of Infant Study Supported by Review of Stage 1 Safety and Tolerability Data ---- Company Expects to Announce VAX-31 ...
Medscape3d
Are Current Antibiotic Guidelines Still Effective for Managing Uncomplicated UTI?
First-line antibiotics for uncomplicated UTI remain more effective than fluoroquinolones and beta-lactams in a retrospective ...
Nabriva Therapeutics (NASDAQ:NBRV) Research Coverage Started at StockNews.com
StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Free Report) in a report published on Thursday. The brokerage issued a hold rating on the biotechnology company’s stock.